Case Report: The role of BRAF mutation in adjuvant and neoadjuvant treatment of melanoma patients: what is the optimal approach?

BackgroundWhile the benefit of adjuvant therapy is well established in patients with stage IIIB–IIID melanoma, its role in stage IIIA disease remains a matter of discussion. This subgroup is generally considered to be at lower risk of recurrence, whereas currently available treatments are associated...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Francesca Romana Di Pietro, Rosa Falcone, Sofia Verkhovskaia, Giulia Poti, Cristina Maria Failla, Maria Luigia Carbone, Maria Francesca Morelli, Albina Rita Zappalà, Roberto Morese, Zorika Christiana Di Rocco, Gabriele Piesco, Paolo Chesi, Paolo Marchetti, Federica De Galitiis
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Frontiers Media S.A. 2026-04-01
Ráidu:	Frontiers in Oncology
Fáttát:	adjuvant treatment BRAF mutation III stage melanoma neoadjuvant strategy
Liŋkkat:	https://www.frontiersin.org/articles/10.3389/fonc.2026.1775350/full
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!